Trilaciclib
Trilaciclib is a transient CDK4/6 inhibitor administered intravenously prior to chemotherapy. It protects hematopoietic stem and progenitor cells in the bone marrow from chemotherapy-induced damage, thereby reducing the risk of myelosuppression. This medication is indicated to reduce the incidence of chemotherapy-induced myelosuppression in adults with extensive-stage small cell lung cancer.
Trilaciclib is a bone marrow protective agent that temporarily inhibits CDK4/6 to reduce chemotherapy-induced low blood cell counts in certain lung cancer patients.
Key facts at a glance
- ATC
- V03AF12
- RxNorm
- 2479690
- Generic
- Trilaciclib
- Class
- atc-v03
- Brands
- Cosela
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Trilaciclib is indicated to reduce the incidence of chemotherapy-induced myelosuppression in adults with extensive-stage small cell lung cancer (ES-SCLC). It is administered as an intravenous infusion prior to chemotherapy regimens containing platinum and etoposide.
Trilaciclib acts as a transient inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are essential for cell cycle progression. By temporarily arresting hematopoietic stem and progenitor cells in the G1 phase of the cell cycle, it shields these cells from chemotherapy-induced damage. This protection allows HSPCs to survive chemotherapy and continue producing neutrophils, red blood cells, and platelets.
Common side effects may include fatigue, headache, and infusion-related reactions. Trilaciclib is contraindicated in patients with known hypersensitivity to the drug or its components. It should be administered before chemotherapy on the same day. Regular monitoring of blood cell counts may be necessary during treatment. The safety and efficacy in pediatric patients have not been established.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy